Research Chemicals
Tesofensine: Weight Loss & Metabolic Optimization
Tesofensine is a triple monoamine reuptake inhibitor… dramatic weight loss results of 10-14kg over 24 weeks… roughly five times more effective than placebo. At the optimal dose of 0.5mg daily, participants experienced 9-11% body weight reduction… side effects like increased heart rate, dry mouth, and insomnia require careful monitoring… not yet approved for commercial use.
01
Understanding Tesofensine
- Class: triple monoamine reuptake inhibitor (dopamine, norepinephrine, serotonin).
- Originally developed for Alzheimer's/Parkinson's.
- Not approved for commercial use.
- Currently in a Phase III trial for hypothalamic obesity (ClinicalTrials.gov).
02
The Science (Triple Threat Mechanism)
Reconstructed from the values stated in the source.
| Neurotransmitter | Function | Effect |
|---|---|---|
| Dopamine | motivation/reward | diet adherence |
| Norepinephrine | energy/metabolism | +24% metabolic rate |
| Serotonin | appetite/satiety | -30-40% caloric intake |
03
Clinical Trial Results
- TIPO-4 (48 weeks): 0.5mg maintained 13-14kg of weight loss.
- Astrup et al. 2008 (Nature): placebo-adjusted weight loss of 4.7%, 9.2%, and 10.4% across the dose range.
TIPO-1, 24 weeks. Reconstructed from the values stated in the source.
| Dose | Weight Loss (%) | Weight Loss (kg) |
|---|---|---|
| 0.25mg | 4.5% | 6.7kg |
| 0.5mg | 9.2% | 11.3kg |
| 1.0mg | 10.6% | 12.8kg |
| Placebo | 2.0% | 2.2kg |
04
Outcomes at the Optimal Dose (0.5mg)
At 0.5mg. Reconstructed from the values stated in the source.
| Measure | Change |
|---|---|
| Weight | -9-11% |
| Waist | -8-10cm |
| Metabolic rate | +24% |
| Appetite | -40% |
| Energy | improved |
05
Dosing Protocol
- Start at 0.25mg daily for 2-4 weeks.
- Optimal dose: 0.5mg daily.
- Maximum: 1.0mg daily (less favorable side-effect profile).
- Morning administration; can be split as 0.25mg twice daily.
06
Safety Profile
- Common side effects: dry mouth (20-30%), insomnia, constipation, headache, nausea.
- Cardiovascular effects are dose-dependent (minimal at 0.25mg, pronounced at 1.0mg).
- Contraindications: uncontrolled hypertension, significant cardiovascular disease, psychiatric history, concurrent monoamine drugs.
07
Stacking
- Stacks with caffeine, L-theanine, metformin, and AOD9604.
References
- 01Int J Obesity — https://www.nature.com/articles/ijo201087
- 02PLOS ONE — https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0300544
- 03TIPO-1 source — https://www.clinicaltrialsarena.com/projects/tesofensine/
- 04Wikipedia — https://en.wikipedia.org/wiki/Tesofensine
- 05Nature — https://www.nature.com/articles/ncpgasthep1327-nrgastro
- 06PubMed — https://pubmed.ncbi.nlm.nih.gov/35294397/
- 07NCBI — https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7787121/
- 08Biohackers World
- 09Valhalla Vitality
This profile is being expanded — additional sections from the source are still being added.
Related in the library